TWI612057B - 可促進傷口癒合、膠原蛋白增生、血管新生、活化免疫細胞並降低傷口感染之胜肽及其應用 - Google Patents
可促進傷口癒合、膠原蛋白增生、血管新生、活化免疫細胞並降低傷口感染之胜肽及其應用 Download PDFInfo
- Publication number
- TWI612057B TWI612057B TW104135487A TW104135487A TWI612057B TW I612057 B TWI612057 B TW I612057B TW 104135487 A TW104135487 A TW 104135487A TW 104135487 A TW104135487 A TW 104135487A TW I612057 B TWI612057 B TW I612057B
- Authority
- TW
- Taiwan
- Prior art keywords
- peptide
- expression
- peptides
- angiogenesis
- present
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 73
- 230000033115 angiogenesis Effects 0.000 title claims abstract description 15
- 230000001737 promoting effect Effects 0.000 title claims abstract description 12
- 230000029663 wound healing Effects 0.000 title claims abstract description 11
- 230000000694 effects Effects 0.000 title abstract description 26
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract description 23
- 230000004913 activation Effects 0.000 title abstract description 3
- 230000037319 collagen production Effects 0.000 title 1
- 210000002865 immune cell Anatomy 0.000 claims abstract description 19
- 206010048038 Wound infection Diseases 0.000 claims abstract description 9
- 230000003213 activating effect Effects 0.000 claims abstract description 4
- 230000001603 reducing effect Effects 0.000 claims abstract 3
- 230000014509 gene expression Effects 0.000 claims description 43
- 102000003777 Interleukin-1 beta Human genes 0.000 claims description 16
- 108090000193 Interleukin-1 beta Proteins 0.000 claims description 16
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims description 15
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 14
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims description 14
- 239000000203 mixture Substances 0.000 claims description 10
- 101000617130 Homo sapiens Stromal cell-derived factor 1 Proteins 0.000 claims description 9
- 102000004890 Interleukin-8 Human genes 0.000 claims description 9
- 108090001007 Interleukin-8 Proteins 0.000 claims description 9
- 102100021669 Stromal cell-derived factor 1 Human genes 0.000 claims description 9
- 102000003814 Interleukin-10 Human genes 0.000 claims description 8
- 108090000174 Interleukin-10 Proteins 0.000 claims description 8
- 230000001105 regulatory effect Effects 0.000 claims 1
- 241000723298 Dicentrarchus labrax Species 0.000 abstract description 33
- 206010052428 Wound Diseases 0.000 abstract description 26
- 208000027418 Wounds and injury Diseases 0.000 abstract description 26
- 102000008186 Collagen Human genes 0.000 abstract description 12
- 108010035532 Collagen Proteins 0.000 abstract description 12
- 229920001436 collagen Polymers 0.000 abstract description 12
- 210000001519 tissue Anatomy 0.000 abstract description 8
- 230000035755 proliferation Effects 0.000 abstract description 7
- 210000002950 fibroblast Anatomy 0.000 abstract description 4
- 210000002510 keratinocyte Anatomy 0.000 abstract description 4
- 230000001338 necrotic effect Effects 0.000 abstract description 4
- 230000002155 anti-virotic effect Effects 0.000 abstract 1
- 230000001580 bacterial effect Effects 0.000 abstract 1
- 230000036039 immunity Effects 0.000 abstract 1
- 230000002980 postoperative effect Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 35
- 239000002158 endotoxin Substances 0.000 description 21
- 229920006008 lipopolysaccharide Polymers 0.000 description 21
- 239000000284 extract Substances 0.000 description 16
- 241000269799 Perca fluviatilis Species 0.000 description 15
- 206010061218 Inflammation Diseases 0.000 description 14
- 230000004054 inflammatory process Effects 0.000 description 14
- 230000006698 induction Effects 0.000 description 10
- 241000251468 Actinopterygii Species 0.000 description 8
- 108020004999 messenger RNA Proteins 0.000 description 8
- 239000004365 Protease Substances 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 239000012535 impurity Substances 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- 108090000526 Papain Proteins 0.000 description 3
- 239000012190 activator Substances 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 229940055729 papain Drugs 0.000 description 3
- 235000019834 papain Nutrition 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- 210000003491 skin Anatomy 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 230000037314 wound repair Effects 0.000 description 3
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 108010004032 Bromelains Proteins 0.000 description 2
- 235000008733 Citrus aurantifolia Nutrition 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 102000057297 Pepsin A Human genes 0.000 description 2
- 108090000284 Pepsin A Proteins 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- -1 Protamex Proteins 0.000 description 2
- 238000010802 RNA extraction kit Methods 0.000 description 2
- 102000005158 Subtilisins Human genes 0.000 description 2
- 108010056079 Subtilisins Proteins 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 235000011941 Tilia x europaea Nutrition 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 235000019835 bromelain Nutrition 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 239000006227 byproduct Substances 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 108010007119 flavourzyme Proteins 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 108010059345 keratinase Proteins 0.000 description 2
- 239000004571 lime Substances 0.000 description 2
- 235000013372 meat Nutrition 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 108010009355 microbial metalloproteinases Proteins 0.000 description 2
- 229940111202 pepsin Drugs 0.000 description 2
- 238000001223 reverse osmosis Methods 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- GUAHPAJOXVYFON-ZETCQYMHSA-N (8S)-8-amino-7-oxononanoic acid zwitterion Chemical compound C[C@H](N)C(=O)CCCCCC(O)=O GUAHPAJOXVYFON-ZETCQYMHSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- XRAYWKDMFVKUTJ-UHFFFAOYSA-N 2-chloro-n-[[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]methyl]acetamide Chemical compound O=C1C=2C(CNC(=O)CCl)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O XRAYWKDMFVKUTJ-UHFFFAOYSA-N 0.000 description 1
- 239000005909 Kieselgur Substances 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 238000010306 acid treatment Methods 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000010805 cDNA synthesis kit Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000004042 decolorization Methods 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000010408 film Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 235000021289 health related food Nutrition 0.000 description 1
- 239000000413 hydrolysate Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 238000012958 reprocessing Methods 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/461—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from fish
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Dermatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Epidemiology (AREA)
- Marine Sciences & Fisheries (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
本發明提供一種新穎胜肽序列(SEQ NO：1~11)，其可萃取自鱸魚，該胜肽具有對抗病毒、細菌、降低傷口感染，並清理壞死組織、幫助傷口清瘡、招集活化更多免疫細胞，同時幫助纖維組織分泌膠原蛋白，活化纖維母細胞與角質細胞、促進血管新生等功效。因此，該些胜肽對於促進傷口癒合、膠原蛋白增生、血管新生、活化免疫細胞與降低傷口感染均具有良好之效果，適合開發作為保健素材，供給體弱或術後修復者使用，幫助其復原並增進其免疫力。
Description
本發明係關於一種胜肽，尤其係關於一種能應用於促進傷口癒合、膠原蛋白增生、血管新生、活化免疫細胞並降低傷口感染之胜肽。
一般人受傷或經手術之後，無論是傷口的復原以及氣力的恢復，都需要較長時間的靜養，並配合適當的飲食，才能達到最好的恢復效果。若欲提早康復，最常見者就是食用能夠讓傷口快速癒合的食品、補品或藥品，例如鱸魚湯等鱸魚萃取物。
2013年台灣之鱸魚產量約為26,094噸，總產值高達21.8億元，除一般家庭、餐廳之直接食用外，有多數鱸魚被為加工製品，而其再製後產生之副產物，其中魚皮與魚骨所占比例竟高達30%，若能妥善加以應用，不但可增進台灣漁業之附加價值，更可有效解決鱸魚加工副產物之處理問題。
為獲悉鱸魚萃取物中具效果之成分，本發明確認其中有效之胜肽成分，遂提供一種可促進傷口癒合、膠原蛋白增生、血管新生、活化免疫細胞並降低傷口感染之胜肽，該胜肽包括選自SEQ ID NO：1至SEQ ID NO：11，及其組合之胜肽所組成的群組。
在本發明的一實施例中，該鱸魚萃取物係萃取自鱸魚的魚皮、鱗片、魚骨或魚肉。
在本發明的一實施例中，該鱸魚萃取物係以角蛋白酶(Keratinase)、胰蛋白酶(Trypsin)、菠蘿蛋白酶(Bromelain)、木瓜蛋白酶(Papain)、胃蛋白酶(Pepsin)、鹼性蛋白酶(Alcalase)、中性蛋白酶(Neutrase)、複合蛋白酶(Protamex)以及風味蛋白酶(Flavourzyme)所組成的群組萃取後而獲得。
在本發明的一態樣中，提供一種胜肽用於促進傷口癒合之用途，該胜肽包括如前所述之胜肽。
在本發明的另一態樣中，提供一種傷口癒合促進劑，包括如前所述之胜肽。此外，在一態樣中，亦提供所述胜肽於製備傷口癒合醫藥組成物之用途。
在本發明的一態樣中，提供一種胜肽用於促進膠原蛋白增生之用途，該胜肽包括如前所述之胜肽。
在本發明的另一態樣中，提供一種膠原蛋白增生促進劑，包括如前所述之胜肽。
在本發明的一態樣中，提供一種胜肽用於促進血管增生之用途，該胜肽包括如前所述之胜肽。此外，在一態樣中，亦提供所述胜肽於製備促進血管增生醫藥組成物之用途。
在本發明的另一態樣中，提供一種血管增生促進劑，包括如前所述之胜肽。
在本發明的一態樣中，提供一種胜肽用於活化免疫細胞之用途，該胜肽包括如前所述之胜肽。此外，在一態樣中，亦提供所述胜肽於製備活化免疫細胞醫藥組成物之用途。
在本發明的另一態樣中，提供一種免疫細胞活化劑，包括如前所述之胜肽。
藉由本發明實施例之胜肽，可誘發TNF-α與IL-1 β的表現量，因此可對抗病毒、細菌、降低傷口感染，並清理壞死組織、幫助傷口清瘡，促進傷口的修復。此外，藉由本發明實施例之胜肽，亦可誘發IL-8與CXCL12的表現，使促進傷口處能夠招集更多的免疫細胞，並活化更多的免疫細胞。再一方面，本發明實施例之胜肽，能夠抑制IL-10的表現，因而能有效促進纖維組織分泌膠原蛋白，幫助傷口的修護與癒合。同時，藉由本發明實施例之胜肽，還可因為活化TNF-α與IL-1 β的表現，進一步可活化纖維母細胞與角質細胞，而具有促進血管新生的效用。
由於本發明所提供之胜肽具有前述之功效，因此在本發明的一實施例中，可進一步利用本發明之胜肽應用於製備相關功效之組合物或試劑，例如傷口癒合促進劑、膠原蛋白增生促進劑、血管增生促進劑或免疫細胞活化劑。
圖1係本發明實施例之胜肽於細胞模擬傷口發炎下，對細胞IL-1 β其mRNA表現影響之結果圖。
圖2係本發明實施例之胜肽於細胞模擬傷口發炎下，對細胞TNF-α其mRNA表現影響之結果圖。
圖3係本發明實施例之胜肽於細胞模擬傷口發炎下，對細胞IL-8其mRNA表現影響之結果圖。
圖4係本發明實施例之胜肽於細胞模擬傷口發炎下，對細胞CXCL12其mRNA表現影響之結果圖。
圖5係本發明實施例之胜肽於細胞模擬傷口發炎下，對細胞IL-10其mRNA表現影響之結果圖。
圖6係本發明實施例之胜肽於細胞模擬傷口發炎下，對細胞IL-1 β其mRNA表現影響之結果圖。
圖7係本發明實施例之胜肽於細胞模擬傷口發炎下，對細胞TNF-α其mRNA表現影響之結果圖。
本發明實施例胜肽之取得，首先須先處理鱸魚樣本，將其以酸處理後進行萃取，萃取出之混合物再以複合型酵素進行水解，然後將水解產物過濾純化後即可獲得。後續則針對該些胜肽進行定序以及相關之功效試驗，以下將進一步詳細說明之。
實施例1 鱸魚萃取物之製備方法
首先，將鱸魚以切片機剪切為約2至6cm大小作為原料，其中該鱸魚部位包含魚皮、鱗片、魚骨與魚肉；之後以2至5倍體積的RO逆滲透水進行原料清洗，重覆清洗鱸魚2至3次以去除血水與雜質。
之後，以1：5的鱸魚與酸液(w/v)比率進行酸處理，其中酸之種類與濃度為1至5%鹽酸、硫酸或磷酸。將鱸魚於15至20℃浸泡10至48小時後，以2至5倍體積RO逆滲透水清洗酸處理後之原料，重覆清洗2至3次進行去酸，最後並以碳酸鈣調整pH值為4至8之間。
鱸魚樣本備妥後，開始以55至100℃熱水進行萃取1至6小時；之後以3000rpm離心10分鐘，進行脫渣過濾；再以0.2-1%之碳酸鈣或石灰去雜質並澄清化；然後以1-10μm的濾膜進行過濾；之後再以離子交換樹脂管柱吸附過濾，去除雜質與石灰，以進一步將效性胜肽分離純化；純化後之效性胜肽經由活性碳脫臭與脫色處理，置於50至60℃下進行減壓濃縮，濃縮其10至20倍。
接著，添加複合型酵素並於40至60℃進行水解1至5小時，其中該複合型酵素包含0.01%-0.1%之角蛋白酶(Keratinase)與菠蘿蛋白酶(Bromelain)；0.1-5%之木瓜蛋白酶(Papain)、胰蛋白酶(Trypsin)與胃蛋白酶(Pepsin)、0.1-5%鹼性蛋白酶(Alcalase)、中性蛋白酶(Neutrase)、複合蛋白酶(Protamex)以及風味蛋白酶(Flavourzyme)。水解完成後，於85至95℃下反應10至30分鐘進行酵素失活；之後將其冷卻；冷卻後以矽藻土與活性碳進行
過濾，使胜肽萃取液澄清化與脫臭，之後再進行一次過濾，將過濾後產物進行超高溫滅菌(Ultra-high temperature，UHT)，於135至140℃下進行殺菌3至5秒；最後以0.2μm濾膜過濾除菌與去除細小雜質後即可獲得本發明所需包含多種胜肽之鱸魚萃取物。
實施例2 鱸魚萃取物中胜肽之定序
鱸魚胜肽萃取物經適當稀釋後，經離心(13000rpm,2min)吸取200μl上清液，以C18-ZipTip(Millpore)去鹽濃縮，樣品回溶後取1/2體積，以下列條件進行LC-MS/MS分析。MS/MS圖譜利用Mascot分析程式進行資料庫檢索分析以得到分析結果。
反應條件：
質譜儀：LTQ XL(Thermo Scientific)
LC系統：Agilent 1200 Series
緩衝溶液A：ddH2O/0.1% formic acid
緩衝溶液B：100% ACN/0.1% formic acid
分析管柱：C18 reverse phase column
梯度表：
經胺基酸定序後，確認其中11種胜肽，其胺基酸序列如表1所示之SEQ ID NO：1~11。
實施例3 免疫細胞之基因表現量分析
將人類THP-1細胞(人類單核球細胞株)分養在6孔細胞培養盤(5*105cell/well)，並將其分組個別進行脂多醣(Lipopolysaccharide，以下簡稱LPS)處理，處理方式如表2所示。
將各組經不同反應物與時間處理後之細胞加以蒐集後，以RNA分離套組(GeneMark RNA isolation kit)分離細胞中之RNA，再經由cDNA合成套組(Roche Transcriptor First Strand cDNA Synthhesis Kit)合成出cDNA，之後利用即時聚合酶連鎖反應套組(SYBR Green Master Mix,KAPA公司)測定目標基因，並由ABI Step one軟體進行基因表現之分析，以從基因表現層面探討鱸魚萃取物對免疫細胞之影響與功效，其結果如圖1至圖7所示。
請先參閱圖1，該圖係本發明實施例鱸魚萃取物中之胜肽於細胞模擬傷口發炎下，對細胞IL-1 β其mRNA表現影響之結果圖。由圖1顯示，以LPS處理THP-1細胞株之IL-1 β表現量會上升，在LPS誘導6小時下，再以1%與2%鱸魚胜肽處理3小時之IL-1 β表現量分別為對照組(LPS_6hr)之4.8與7.9倍，而在LPS誘導9小時下，再以1%與2%鱸魚胜肽處理6小時之IL-1 β表現量則分別為對照組(LPS_9hr)之4.3與8.7倍。
請再參閱圖2，該圖係本發明實施例鱸魚萃取物中之胜肽於細胞模擬傷口發炎下，對細胞TNF-α其mRNA表現影響之結果圖。由圖2結果顯示，以LPS處理THP-1細胞株之TNF-α表現量會上升，在LPS誘導6小時下再以1%與2%鱸魚胜肽處理3小時之TNF-α表現量分別為對照組(LPS_6hr)之3與3.5倍，而在LPS誘導9小時下，再以1%與2%鱸魚胜肽處理6小時之TNF-α表現量分別為對照組(LPS_9hr)之2.3與4倍，而誘發TNF-α與IL-1 β對於傷口修護扮演著重要角色，其表現量的增加可對抗病毒、細菌、降低傷口感染，並清理壞死組織、幫助傷口清瘡。
請參閱圖3，該圖係本發明實施例鱸魚萃取物中之胜肽於細胞模擬傷口發炎下，對細胞IL-8其mRNA表現影響之結果圖。由圖3結果顯
示，以LPS處理THP-1細胞株之IL-8表現量會上升，在LPS誘導6小時下再以1%與2%鱸魚胜肽處理3小時之IL-8表現量分別為對照組(LPS_6hr)之7.6與6.3倍，而在LPS誘導9小時下，再以1%與2%鱸魚胜肽處理6小時之IL-8表現量分別為對照組(LPS_9hr)之4.7與7.9倍。
請參閱圖4，該圖係本發明實施例鱸魚萃取物中之胜肽於細胞模擬傷口發炎下，對細胞CXCL12其mRNA表現影響之結果圖。由圖4結果顯示，以LPS處理THP-1細胞株之CXCL12表現量會上升，在LPS誘導6小時下再以1%與2%鱸魚胜肽處理3小時之CXCL12表現量分別為對照組(LPS_6hr)之1.9與3倍，而在LPS誘導9小時下，再以1%與2%鱸魚胜肽處理6小時之CXCL12表現量分別為對照組(LPS_9hr)之1.7與3.2倍，而誘發IL-8與CXCL12表現量可促進免疫系統於傷口處招集更多免疫細胞，並同時活化更多免疫細胞。
請參閱圖5，該圖係本發明實施例鱸魚萃取物中之胜肽於細胞模擬傷口發炎下，對細胞IL-10其mRNA表現影響之結果圖。由圖5結果顯示，以LPS處理THP-1細胞株之IL-10表現量會下降，在LPS誘導27小時下再以1%與2%鱸魚胜肽處理24小時之IL-10相較於對照組(LPS_27hr)分別減少了54%與30%的表現量，而抑制IL-10表現的效果，係能有效促進纖維組織分泌膠原蛋白，因此能幫助傷口的修護與癒合。
請同時參閱圖6、7，該二圖分別係本發明實施例鱸魚萃取物中之胜肽於細胞模擬傷口發炎下，對細胞IL-1 β與TNF-α其mRNA表現影響之結果圖。由圖6結果顯示，以LPS處理THP-1細胞株之IL-1 β表現量會上升，在LPS誘導27小時下，再以1%與2%鱸魚胜肽處理24小時之IL-1 β表現量分別為對照組(LPS_27hr)之3.3與5.1倍，而由圖7結果顯示，以LPS處理THP-1細胞株之TNF-α表現量會上升，在LPS誘導27小時下再以2%鱸魚胜肽處理24小時之TNF-α表現量為對照組(LPS_27hr)之2.3倍，而活化TNF-α與IL-1 β的表現量，亦可同時活化纖維母細胞與角質細胞，因而具有促進血管新生的功效。
因此，透過前述細胞模擬傷口發炎狀態下，IL-1 β、TNF-α、
IL-8、IL-10以及CXCL12表現量之變化影響，可確知本發明所提供之胜肽，能夠使傷口處能夠招集更多的免疫細胞，並活化更多的免疫細胞，具有對抗病毒、細菌、降低傷口感染，並清理壞死組織、幫助傷口清瘡，促進傷口的修復的功效。同時因為可有效促進纖維組織分泌膠原蛋白，更加能夠幫助傷口的修護與癒合。此外，由於該胜肽可活化TNF-α與IL-1 β的表現，而能進一步活化纖維母細胞與角質細胞，因此亦具有促進血管新生的效用。
由於本發明所提供之胜肽具有前述之功效，因此可進一步利用本發明之胜肽應用於製備相關功效之組合物或試劑，例如傷口癒合促進劑、膠原蛋白增生促進劑、血管增生促進劑或是免疫細胞活化劑。該些組合物或試劑可包括有效劑量之本發明胜肽以及賦形劑或載劑等，因此該組合物或試劑形式可為藥錠、膠囊、液狀、凝膠、漿液、懸浮液、粉包、敷料、乳液、噴劑、膜狀物，並未設有特別的限制。進一步，前述組合物或試劑依其利用方式，亦可製備成飲食品應用於保健相關食品，或是輔助用作外用品。
<110> 大江生醫股份有限公司
<120> 可促進傷口癒合、膠原蛋白增生、血管新生、活化免疫細胞並降低傷口感染之胜肽及其應用
<130> 104B0345-I1
<140> 104135487
<141> 2015-10-28
<160> 11
<170> PatentIn Version 3.5
<210> 1
<211> 24
<212> PRT
<213> 鱸魚
<400> 1
<210> 2
<211> 17
<212> PRT
<213> 鱸魚
<400> 2
<210> 3
<211> 19
<212> PRT
<213> 鱸魚
<400> 3
<210> 4
<211> 10
<212> PRT
<213> 鱸魚
<400> 4
<210> 5
<211> 24
<212> PRT
<213> 鱸魚
<400> 5
<210> 6
<211> 19
<212> PRT
<213> 鱸魚
<400> 6
<210> 7
<211> 52
<212> PRT
<213> 鱸魚
<400> 7
<210> 8
<211> 18
<212> PRT
<213> 鱸魚
<400> 8
<210> 9
<211> 23
<212> PRT
<213> 鱸魚
<400> 9
<210> 10
<211> 17
<212> PRT
<213> 鱸魚
<400> 10
<210> 11
<211> 5
<212> PRT
<213> 鱸魚
<400> 11
Claims (2)
- 一種用於製備調節TNF-α、IL-1 β、IL-8、CXCL12或IL-10表現之組合物之用途，其中該組合物包括SEQ ID NO：1至SEQ ID NO：11所構成胜肽之組合。
- 如申請專利範圍第1項所述之用途，進一步包括用於製備促進血管新生、降低傷口感染、促進傷口癒合或活化免疫細胞之組合物。
Priority Applications (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| TW104135487A TWI612057B (zh) | 2015-10-28 | 2015-10-28 | 可促進傷口癒合、膠原蛋白增生、血管新生、活化免疫細胞並降低傷口感染之胜肽及其應用 |
| CN201610051300.1A CN106632641B (zh) | 2015-10-28 | 2016-01-26 | 可促进伤口愈合、胶原蛋白增生、血管新生、活化免疫细胞并降低伤口感染的胜肽及其应用 |
| JP2016209132A JP6650861B2 (ja) | 2015-10-28 | 2016-10-26 | 傷口の癒合、コラーゲン増殖、血管新生、免疫細胞の活性化を促進し、また傷口の感染を減少させることができるペプチド及びその応用 |
| US15/336,212 US10005823B2 (en) | 2015-10-28 | 2016-10-27 | Peptides having effects on promoting wound healing, collagen production, angiogenesis, activation of immunocytes and applications thereof |
| KR1020160141003A KR20170049432A (ko) | 2015-10-28 | 2016-10-27 | 상처 유합, 콜라겐 생성, 혈관 신생, 면역세포 활성화를 촉진시키고 상처 감염을 저감시킬 수 있는 펩티드 및 이의 용도 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| TW104135487A TWI612057B (zh) | 2015-10-28 | 2015-10-28 | 可促進傷口癒合、膠原蛋白增生、血管新生、活化免疫細胞並降低傷口感染之胜肽及其應用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TW201714893A TW201714893A (zh) | 2017-05-01 |
| TWI612057B true TWI612057B (zh) | 2018-01-21 |
Family
ID=58635339
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW104135487A TWI612057B (zh) | 2015-10-28 | 2015-10-28 | 可促進傷口癒合、膠原蛋白增生、血管新生、活化免疫細胞並降低傷口感染之胜肽及其應用 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US10005823B2 (zh) |
| JP (1) | JP6650861B2 (zh) |
| KR (1) | KR20170049432A (zh) |
| CN (1) | CN106632641B (zh) |
| TW (1) | TWI612057B (zh) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107164442B (zh) * | 2017-06-05 | 2020-10-13 | 深圳知本康业有限公司 | 一种胶原蛋白多肽及应用 |
| CN107383164B (zh) * | 2017-07-03 | 2019-10-11 | 择天生物科技（大连）有限公司 | 一类用于促胶原分泌的超短肽及其应用 |
| US10758559B1 (en) | 2017-09-01 | 2020-09-01 | University Of Wyoming | Targeting cathepsin K to facilitate wound healing |
| US11766467B2 (en) | 2017-09-01 | 2023-09-26 | University Of Wyoming | Methods of treating wounds using cathepsin K inhibitors |
| TWI674276B (zh) * | 2017-09-29 | 2019-10-11 | 三凡生技研發股份有限公司 | 促進傷口癒合之胜肽、其組合物及其使用方法 |
| US10232009B1 (en) * | 2017-09-29 | 2019-03-19 | Pro Sunfun Biotech Research And Development Co., Ltd. | Peptide for promoting wound healing, its composition and method of using the same |
| AU2018375151A1 (en) * | 2017-11-29 | 2020-06-11 | Figene, Llc | Interaction of fibroblasts and immune cells for activation and uses thereof |
| WO2023200875A1 (en) * | 2022-04-13 | 2023-10-19 | ALASTIN Skincare, Inc. | Octapeptide for topical application |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8298548B2 (en) * | 2007-07-18 | 2012-10-30 | Solazyme, Inc. | Compositions for improving the health and appearance of skin |
| CN101113171A (zh) * | 2006-07-26 | 2008-01-30 | 吴金洌 | 一种用以增加动物摄食量的胜肽 |
| EP2288376B1 (en) * | 2008-04-18 | 2016-01-13 | Collplant Ltd. | Methods of generating and using procollagen |
| US8349799B1 (en) * | 2012-01-07 | 2013-01-08 | Gp Medical, Inc. | Pharmaceutical composition of nanoparticles |
| CN104248751A (zh) * | 2013-06-28 | 2014-12-31 | 东吴大学 | 抗癌胜肽、其用途以及含有该胜肽的医药组成物 |
| CN104293868A (zh) * | 2013-07-18 | 2015-01-21 | 张明焕 | 鱼鳞胶原蛋白胜肽的制备方法 |
-
2015
- 2015-10-28 TW TW104135487A patent/TWI612057B/zh active
-
2016
- 2016-01-26 CN CN201610051300.1A patent/CN106632641B/zh active Active
- 2016-10-26 JP JP2016209132A patent/JP6650861B2/ja active Active
- 2016-10-27 KR KR1020160141003A patent/KR20170049432A/ko not_active Application Discontinuation
- 2016-10-27 US US15/336,212 patent/US10005823B2/en active Active
Non-Patent Citations (5)
| Title |
|---|
| Asahina, K., et al.," Expression of Genes of Type I and Type II Collagen in the Formation and Development of the Blastema of Regenerating Newt Limb", Dev. Dyn., 1999, Vol.216, Issue 1, P.59-71. * |
| NCBI GenBank:BAF72200.1， 2008/10/02。 * |
| NCBI GenBank:XP 010745684.1， 2014/12/18。 * |
| 張子薇等人，《魚鱗膠原蛋白對小鼠皮膚傷口癒合的影響》，牡丹江醫學院學報，2015年4月，第36卷，第2期，第21-23頁。 * |
| 朱偉等人，《魚鱗膠原蛋白對免疫低下小鼠皮膚傷口癒合的影響》，哈爾濱醫科大學學報，2014年6月，第48卷，第3期，第177-181頁。 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN106632641A (zh) | 2017-05-10 |
| US10005823B2 (en) | 2018-06-26 |
| TW201714893A (zh) | 2017-05-01 |
| US20170121378A1 (en) | 2017-05-04 |
| JP2017081912A (ja) | 2017-05-18 |
| KR20170049432A (ko) | 2017-05-10 |
| JP6650861B2 (ja) | 2020-02-19 |
| CN106632641B (zh) | 2019-10-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI612057B (zh) | 可促進傷口癒合、膠原蛋白增生、血管新生、活化免疫細胞並降低傷口感染之胜肽及其應用 | |
| US10455849B2 (en) | Method for the preparation of a protein peptide, a protein peptide and use thereof | |
| CN106519020B (zh) | 一种具有美容功效的功能性肽及其制备方法和用途 | |
| Lacroix et al. | Inhibition of dipeptidyl peptidase (DPP)-IV and α-glucosidase activities by pepsin-treated whey proteins | |
| TWI516212B (zh) | 結合壓力與酵素萃取燕窩之方法 | |
| CN104710511B (zh) | 一种源于带鱼鱼肉蛋白的铁螯合肽及其制备方法和用途 | |
| CN103305580A (zh) | 一种以哺乳动物皮及骨为原料制备胶原蛋白肽的方法 | |
| Sarker | A review on the application of bioactive peptides as preservatives and functional ingredients in food model systems | |
| JP2012244930A (ja) | かつおの中骨を原料とするコラーゲンペプチドの製造方法 | |
| CN107082807B (zh) | 具有ace抑制功能的牦牛骨蛋白肽及制备方法和应用 | |
| Ramachandran et al. | Antihypertensive potential of bioactive hydrolysate from edible bird’s nest | |
| CN113151385B (zh) | 一种制备畜禽软骨胶原蛋白多肽的方法 | |
| JP2012116773A (ja) | Ｉｇｆ−１値上昇剤 | |
| KARAOĞUL et al. | Foods that improving the Immune System against Covid-19 and its infectiousness: Foods against Covid-19 and its infectiousness | |
| CN113122604B (zh) | 一种海肠胶及其制备方法和应用 | |
| Mokhtar et al. | Extraction, optimization and characterization of collagen from chicken (Gallus gallus domesticus) feet | |
| Chandimali et al. | Bioactive peptides derived from duck products and by-products as functional food ingredients | |
| JP7002212B2 (ja) | 疲労回復用組成物及び疲労回復用加圧酵素分解物を製造する方法 | |
| RU2397672C1 (ru) | Способ комплексной переработки топинамбура | |
| TW201634057A (zh) | 具有護骨功效之鱸魚萃取物 | |
| CN112195214B (zh) | 一种鱼皮胶原多肽及其制备方法和应用 | |
| RO133817A0 (ro) | Procedeu de obţinere a unor peptide colagenice antioxidante din piele de peşte de apă dulce | |
| Son et al. | Characterization of lactoferrin hydrolysates on inflammatory cytokine expression in Raw264. 7 macrophages | |
| US20230110281A1 (en) | Process for producing compounds of interest from at least one mineralized connective tissue, and compounds of interest derived from this production process | |
| US20170266252A1 (en) | Glycine max constructs, soy protein sequences, and methods of treating health conditions using the same |